Cancer · 1986 · 113 citations · 28 references
MedicineHematologyOncologyChemotherapyHematologic OncologyMedical OncologyAcute Respiratory Distress SyndromeAdverse Effects Of ChemotherapyAnemiaChemotherapy In Hematologic MalignanciesHematologic MalignanciesHematologic ToxicityAdult Respiratory Distress SyndromeChemotherapy-induced Pulmonary ToxicityChemotherapy-related ToxicityDrug-induced Hemolytic AnemiaHematologic Malignancy ManagementMicroangiopathic Hemolytic AnemiaNeurologic DeficitsSevere Anemia
Chemotherapy is frequently used to treat adenocarcinoma. Thirty-nine cases are reviewed in which the patients developed a hemolytic-uremic-like syndrome, apparently in response to chemotherapy. About 44% of the patients had gastric adenocarcinoma, and 82% had received mitomycin C. Most patients (75%) developed the syndrome 6 to 12 months after starting chemotherapy, and 60% were in remission. Severe microangiopathic hemolytic anemia, thrombocytopenia, and renal impairment were each noted in about 90% of the cases. Neurologic symptoms were usually absent, but 49% of the patients developed adult respiratory distress syndrome (ARDS). The overall case fatality rate was 72%; those patients with ARDS had a 95% mortality rate, while 50% of those without ARDS survived. The half-life of survival of those who ultimately died was 2 months. Treatment is unsatisfactory, although steroids and plasmapheresis may prolong survival.
28
The 1982 revised criteria for the classification of systemic lupus erythematosus
Eng M. Tan, Alan S. Cohen, James F. Fries et al. · Arthritis & Rheumatism · 1982 · 14.6K citations
Thrombotic Thrombocytopenic Purpura
Ren L. Ridolfi, William R. Bell · Medicine · 1981 · 331 citations
Medicine, Hematology, Pathology +7